DelveInsight’s, “Degenerative Disc Disease Pipeline Insight, 2022,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Degenerative Disc Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Degenerative Disc Disease Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Degenerative disc disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Degenerative Disc Disease Pipeline Insight Report

• DelveInsight’s Degenerative Disc Disease Pipeline analysis depicts a robust space with 3o+ active players working to develop 38+ pipeline therapies for Degenerative Disc Disease treatment.
• The leading Degenerative Disc Disease Companies are working such as Affibody, Celgene Corporation, UCB, Vivex Biomedical, Inc., Lynk Pharmaceuticals, Huabo Biopharm, Amgen, Izana Bioscience, Takeda, Merck Serono, MoonLake Immunotherapeutics, and others.
• Promising Degenerative Disc Disease Pipeline Therapies such as Izokibep, CC 99677, Bimekizumab, and others
• Companies and academics are working to assess challenges and seek opportunities that could influence Degenerative disc disease R&D. The therapies under development are focused on novel approaches to treat/improve Degenerative disc disease.

 

Request a sample and discover the recent breakthroughs happening in the Degenerative Disc Disease pipeline landscape @ Degenerative Disc Disease Pipeline Outlook

 

Degenerative Disc Disease Overview

Degenerative disc disease (spondylosis) is used to describe the regular changes that occur in human spinal discs as they age. The discs usually act as shock absorbers for the human spine, which allows the body to flex, bend, and twist. With aging, there are several other factors, such as the drying out of the disc, tears in the outer core of the disc during daily activities, and sports and injuries leading to swelling, soreness, and instability, contributing to the development of degenerative disc disease. This disease often leads to multiple types of disorders, such as lumbar spinal stenosis, spondylolisthesis, and retrospondylolisthesis. About 90% of people experience an episode of debilitating back pain at a later point in their lives. The majority of cases experienced are asymptomatic. The spinal disks are made up of a soft inner core and a tough outer wall.

 

Recent Developmental Activities in the Degenerative Disc Disease Pipeline

• Celgene Corporation, is developing a drug CC 99677, as a treatment for ankylosing spondylitis (AS). The CC-99677 inhibition of MK2 is a promising approach for the treatment of inflammatory diseases. Currently, Phase II study of CC-99677 in patients with, ankylosing spondylitis (AS) is undergoing.
• Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively and directly inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of ankylosing spondylitis.
• Inmagene’s investigational candidate, Izokibep (IMG-020), is a novel bispecific fusion protein, potently targeting both subunits of IL-17A as well as albumin. Izokibep has been specifically designed to utilize the strengths of Affibody’s technology platform to create a very small protein drug (18 kDa, approximately one eighth of the size of an antibody) with very high apparent affinity to IL-17A (KD ~300fM, approximately 1000X of a typical IL-17 antibody) and antibody-like half-life due to the strong (KD ~50pM) binding affinity to serum albumin. These features lead to the potential for best-in-class efficacy in a convenient, less frequent and at-home subcutaneous administration. Izokibep is manufactured in an inexpensive E. coli system, which allows significantly lower manufacturing cost/dose than that of a typical antibody drug. Affibody is developing IMG-020 (izokibep) in a global Phase II clinical trial in the United States, China and South Korea for the treatment of ankylosing spondylitis, with a focus to target hard-to-treat patients by increasing the dose and exposure.

 

Degenerative Disc Disease Emerging Drugs

• Izokibep: Affibody
• CC 99677: Celgene Corporation
• Bimekizumab : UCB

 

Learn more about the novel and emerging Degenerative Disc Disease pipeline therapies @ Degenerative Disc Disease Clinical Trials

 

Degenerative Disc Disease Pipeline Therapeutic Analysis

There are approx. 30+ key companies which are developing the therapies for Degenerative disc disease. The companies which have their Degenerative disc disease drug candidates in the most advanced stage, i.e. phase III include, UCB.

 

Scope of the Degenerative Disc Disease Pipeline Report

• Coverage- Global
• Degenerative disc disease Assessment by Product Type
• Degenerative disc disease Assessment by Stage and Product Type
• Degenerative disc disease Assessment by Route of Administration
• Degenerative disc disease Assessment by Stage and Route of Administration
• Degenerative disc disease Assessment by Molecule Type
• Degenerative disc disease Assessment by Stage and Molecule Type
• Degenerative disc disease Companies- Affibody, Celgene Corporation, UCB, Vivex Biomedical, Inc., Lynk Pharmaceuticals, Huabo Biopharm, Amgen, Izana Bioscience, Takeda, Merck Serono, MoonLake Immunotherapeutics, and others.
• Degenerative disc disease Pipeline Therapies such as Izokibep, CC 99677, Bimekizumab, and others

 

Table of Content

1. Introduction
2. Executive Summary
3. Degenerative disc disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Degenerative disc disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Bimekizumab : UCB
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CC 99677: Celgene Corporation
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Degenerative disc disease Key Companies
21. Degenerative disc disease Key Products
22. Degenerative disc disease- Unmet Needs
23. Degenerative disc disease- Market Drivers and Barriers
24. Degenerative disc disease- Future Perspectives and Conclusion
25. Degenerative disc disease Analyst Views
26. Degenerative disc disease Key Companies
27. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Degenerative disc disease drugs?
• How many Degenerative disc disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Degenerative disc disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Degenerative disc disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Degenerative disc disease and their status?
• What are the key designations that have been granted to the emerging drugs?

 

For further information on the Degenerative Disk Disease pipeline therapeutics, reach out Degenerative Disk Disease Companies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/